TimothyTwaddellMD

PubMed

• Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
  Nemunaitis, J., Eager, R., Twaddell, T., Corey, A., Sekar, K., Tkaczuk, K., Thompson, J., Hoff, P. M., Pazdur, R.> ;J Clin Oncol. 2000 Oct 1
• Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
  Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., ...> ;Semin Oncol. 1999 Aug
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexp...
  Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., Slamon, D. J.> ;J Clin Oncol. 1998 Aug
• Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.
  Eron, J. J., Ashby, M. A., Giordano, M. F., Chernow, M., Reiter, W. M., Deeks, S. G., Lavelle, J. P., Conant, M. A., Yangco, B. G., Pate, P. G., Torres, R. A., Mitsuya...> ;Lancet. 1996 Dec 7
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
  Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., ...> ;J Clin Oncol. 1996 Mar
• Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
  Schwartz, D. H., Gorse, G., Clements, M. L., Belshe, R., Izu, A., Duliege, A. M., Berman, P., Twaddell, T., Stablein, D., Sposto, R.> ;Lancet. 1993 Jul 10
• Join now to see all